Dimensional Fund Advisors LP increased its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 57.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 286,894 shares of the biopharmaceutical company’s stock after buying an additional 104,638 shares during the period. Dimensional Fund Advisors LP owned approximately 0.62% of Xencor worth $6,863,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Primecap Management Co. CA raised its stake in shares of Xencor by 0.4% in the first quarter. Primecap Management Co. CA now owns 5,793,356 shares of the biopharmaceutical company’s stock worth $138,577,000 after buying an additional 24,534 shares during the period. Vanguard Group Inc. raised its stake in shares of Xencor by 5.2% in the first quarter. Vanguard Group Inc. now owns 1,611,115 shares of the biopharmaceutical company’s stock worth $38,537,000 after buying an additional 79,445 shares during the period. Geode Capital Management LLC raised its stake in shares of Xencor by 8.0% in the first quarter. Geode Capital Management LLC now owns 367,230 shares of the biopharmaceutical company’s stock worth $8,783,000 after buying an additional 27,099 shares during the period. Teachers Advisors LLC raised its stake in shares of Xencor by 1.2% in the first quarter. Teachers Advisors LLC now owns 323,782 shares of the biopharmaceutical company’s stock worth $7,745,000 after buying an additional 3,868 shares during the period. Finally, Acadian Asset Management LLC raised its stake in shares of Xencor by 54.5% in the first quarter. Acadian Asset Management LLC now owns 322,768 shares of the biopharmaceutical company’s stock worth $7,722,000 after buying an additional 113,862 shares during the period. Institutional investors and hedge funds own 73.53% of the company’s stock.

Xencor, Inc. (NASDAQ:XNCR) traded up 2.91% on Thursday, reaching $20.18. 101,390 shares of the company’s stock traded hands. Xencor, Inc. has a 52-week low of $18.45 and a 52-week high of $29.38. The stock’s market capitalization is $946.97 million. The firm’s 50-day moving average is $22.39 and its 200 day moving average is $22.90.

Xencor (NASDAQ:XNCR) last posted its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.10. The firm had revenue of $13.34 million during the quarter, compared to analysts’ expectations of $8.15 million. Xencor had a negative net margin of 121.04% and a negative return on equity of 13.79%. Analysts forecast that Xencor, Inc. will post ($1.17) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Xencor, Inc. (XNCR) Position Increased by Dimensional Fund Advisors LP” was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/xencor-inc-xncr-position-increased-by-dimensional-fund-advisors-lp/1520604.html.

A number of equities research analysts have recently issued reports on XNCR shares. Wedbush restated an “outperform” rating and issued a $29.00 target price on shares of Xencor in a research note on Wednesday, May 10th. BidaskClub lowered shares of Xencor from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Zacks Investment Research lowered shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Finally, Canaccord Genuity restated a “buy” rating and issued a $36.00 target price on shares of Xencor in a research note on Tuesday, August 8th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $29.33.

In other Xencor news, major shareholder John S. Stafford III acquired 41,016 shares of the company’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was acquired at an average price of $19.69 per share, for a total transaction of $807,605.04. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bruce L. A. Carter sold 2,366 shares of the firm’s stock in a transaction that occurred on Friday, June 2nd. The shares were sold at an average price of $22.00, for a total transaction of $52,052.00. Following the completion of the transaction, the director now owns 68,578 shares of the company’s stock, valued at approximately $1,508,716. The disclosure for this sale can be found here. In the last quarter, insiders purchased 223,051 shares of company stock valued at $4,536,061 and sold 34,766 shares valued at $739,408. 4.14% of the stock is owned by company insiders.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.